Rate My Professor Meng Lim

Dr. Wei Meng Lim is a Lecturer in the School of Pharmacy at Monash University Malaysia, having joined the institution in April 2022. A registered Malaysian pharmacist, he completed his Master of Pharmacy at the University of Strathclyde in 2008, after which he worked for two years as a pharmacist at Sarawak General Hospital. Lim advanced his academic credentials at the International Medical University (IMU), obtaining a Master of Science in Medical and Health Sciences in 2014 and a PhD in Medical and Health Sciences in 2019. He held various academic positions at IMU from 2010 to 2022.

Lim's research focuses on cancer biology and therapeutics, particularly in the area of drug discovery. He performs in vitro screening of novel compounds on cancer cell lines to determine potency and selectivity, and studies the mechanisms of action along with pathways influencing cancer cell survival. His specific interests include therapeutic targets for endometrial and pancreatic cancers, incorporating high-throughput screening, drug repurposing, combination drug studies, and immuno-oncology. Prominent publications include 'Impact of microplastics and nanoplastics on human health' (Nanomaterials, 2021; 1,071 citations), 'Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease' (International Journal of Pharmaceutics, 2020; 183 citations), 'Antibacterial activity and mode of action of β-caryophyllene on Bacillus cereus' (Polish Journal of Microbiology, 2020; 183 citations), 'Functional roles of JNK and p38 MAPK signaling in nasopharyngeal carcinoma' (International Journal of Molecular Sciences, 2022; 180 citations), 'Optimisation Studies of Mesoporous Silica Nanoparticle as a Drug Carrier for Gemcitabine: Enhancing Therapeutic Effectiveness in Pancreatic Cancer' (2024), 'Polyethylene glycol-phospholipid functionalized single-walled carbon nanotubes for enhanced siRNA systemic delivery' (2024), and 'A stimuli-responsive in situ spray hydrogel co-loaded with naringenin and gentamicin for chronic wounds' (2023). He coordinates the PHR4012 - Professional Practice 5 unit and supervises PhD students.